Reimbursed access to bylvay® (odevixibat) approved in france for patients with pfic 1 & 2

Boston, nov. 30, 2022 (globe newswire) -- albireo pharma, inc. (nasdaq: albo), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced that the committee economic health products (ceps) has approved reimbursed access to bylvay (odevixibat) in france following a favorable clinical assessment from the haute autoritÉ de santÉ (has) for the treatment of progressive familial intrahepatic cholestasis (pfic) types 1 and 2 (except for the bsep3 subtype). a potent, oral, once-daily, non-systemic ileal bile acid transport inhibitor, bylvay has minimal systemic exposure and acts locally in the small intestine as a treatment for pfic, a rare and devastating disorder that affects young children and causes progressive, life-threatening liver disease. bylvay received from the has transparency committee an important smr for its medical benefit and a moderate asmr iii for its improvement in medical benefit.
ALBO Ratings Summary
ALBO Quant Ranking